NCT04549597View on ClinicalTrials.gov

Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia

PHASE4CompletedINTERVENTIONAL
Enrollment

333

Participants

Timeline

Start Date

November 20, 2020

Primary Completion Date

October 13, 2021

Study Completion Date

December 1, 2021

Conditions
Chronic Kidney Disease Requiring Chronic DialysisHyperphosphatemia
Interventions
DRUG

Tenapanor

Use of tenapanor

Trial Locations (1)

33313

South Florida Research Institute, Lauderdale Lakes

Sponsors

Lead Sponsor

Ardelyx
All Listed Sponsors
lead

Ardelyx

INDUSTRY

NCT04549597 - Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia | Biotech Hunter | Biotech Hunter